Bioventus Inc
bioventus.comBioventus Inc (NASDAQ: BVS) is a global medical device company that develops and sells products to relieve pain and treat musculoskeletal conditions. Revenue comes from transactional product sales across three business lines: Pain Treatments and PRP, Surgical Solutions, and Restorative Therapies, with reimbursement from Medicare, Medicaid, and private insurance plans driving demand. The company operates through two reporting segments, U.S. and International, which accounted for 88% and 12% of total net sales, respectively, for the fiscal year ended December 31, 2025. Key products include hyaluronic acid viscosupplementation injections for knee osteoarthritis (GELSYN-3, SUPARTZ), the XCELL PRP System, bone graft products (OSTEOAMP), and the SonicOne ultrasonic debridement system. The company also holds FDA 510(k) clearances for peripheral nerve stimulation devices TalisMann and StimTrial, received in July 2025. CEO Robert E. Claypoole leads the company. Cash and cash equivalents totaled $51.2 million as of December 31, 2025, with net cash from operating activities of $74.7 million for the year ended December 31, 2025.
Products & Services
GELSYN-3 (three-injection HA viscosupplementation for knee osteoarthritis), SUPARTZ (five-injection HA viscosupplementation for knee osteoarthritis), XCELL PRP System (platelet-rich plasma system fully launched in U.S. in August 2025), OSTEOAMP (allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive procedures), SonicOne Ultrasonic Cleansing and Debridement System (wound bed preparation), TalisMann and StimTrial (FDA 510(k)-cleared peripheral nerve stimulation devices for chronic pain, cleared July 2025).
Revenue Model
Transactional product sales of medical devices and biologics, with demand dependent on third-party payer reimbursement from Medicare, Medicaid, and private insurance plans.
Customers & Markets
Physicians in orthopedics, sports medicine, neurosurgery, and wound care specialties. End markets include knee osteoarthritis treatment, bone grafting, wound debridement, and chronic pain management. Reimbursement from Medicare, Medicaid, and private insurers is material to demand.
Geographic Exposure
U.S. segment: 88% of total net sales, FY2025. International segment: 12% of total net sales, FY2025. As of December 31, 2025, $41.3 million of cash held in the U.S. and $9.9 million held internationally.
Loading...
